Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States

AIM: To examine the generalizability of results from glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) cardiovascular outcome trials (CVOTs) in the US type 2 diabetes (T2D) population. MATERIALS AND METHODS: Patients enrolled or eligible for inclusion in four CVOTs (EXSCEL, LEADER, REWIND, and SUS...

Descripción completa

Detalles Bibliográficos
Autores principales: Boye, Kristina S., Riddle, Matthew C., Gerstein, Hertzel C., Mody, Reema, Garcia‐Perez, Luis‐Emilio, Karanikas, Chrisanthi A., Lage, Maureen J., Riesmeyer, Jeffrey S., Lakshmanan, Mark C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593714/
https://www.ncbi.nlm.nih.gov/pubmed/30714309
http://dx.doi.org/10.1111/dom.13649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593714/
https://www.ncbi.nlm.nih.gov/pubmed/30714309
http://dx.doi.org/10.1111/dom.13649

Ejemplares similares